AKT1 and neoplasm: In 2024, Hong et al, engineered T cells to express CCR10-1G4 TCRs, which exhibited enhanced migration toward CCL28 via ERK1/2 and AKT activation and reduced tumor burdens in CCL28 overexpressing A375 melanoma xenografts (129).